Frank J Vocci1, Robert P Schwartz2, Monique E Wilson2, Michael S Gordon3, Timothy W Kinlock4, Terrence T Fitzgerald5, Kevin E O'Grady6, Jerome H Jaffe7. 1. Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA. Electronic address: fvocci@friendsresearch.org. 2. Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA. 3. Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; Stevenson University, Department of Criminal Justice, 1525 Greenspring Valley Road, Stevenson, MD 21153, USA. 4. Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Baltimore, School of Criminal Justice, College of Public Affairs, 1420 N. Charles Street, Baltimore, MD 21201, USA. 5. Glenwood Life Counseling Center, 516 Glenwood Avenue, Baltimore, MD 21212, USA. 6. University of Maryland, 8082 Baltimore Avenue, College Park, MD 20740, USA. 7. Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA; University of Maryland, School of Medicine, Department of Psychiatry, 110 S. Paca Street, Baltimore, MD 21201, USA.
Abstract
BACKGROUND: In a previously reported randomized controlled trial, formerly opioid-dependent prisoners were more likely to enter community drug abuse treatment when they were inducted in prison onto buprenorphine/naloxone (hereafter called buprenorphine) than when they received counseling without buprenorphine in prison (47.5% vs. 33.7%, p=0.012) (Gordon et al., 2014). In this communication we report on the results of the induction schedule and the adverse event profile seen in pre-release prisoners inducted onto buprenorphine. METHOD: This paper examines the dose induction procedure, a comparison of the proposed versus actual doses given per week, and side effects reported for 104 adult participants who were randomized tobuprenorphinetreatment in prison. Self-reported side effects were analyzed using generalized estimated equations to determine changes over time in side effects. RESULTS: Study participants were inducted onto buprenorphine at a rate faster than the induction schedule. Of the 104 (72 males, 32 females) buprenorphinerecipients, 64 (37 males, 27 females) remained on medication at release from prison. Nine participants (8.6%) discontinued buprenorphine because of unpleasant opioid side effects. There were no serious adverse events reported during the in-prison phase of the study. Constipation was the most frequent symptom reported (69 percent). CONCLUSION: Our findings suggest that buprenorphine administered to non-opioid-tolerant adults should be started at a lower, individualized dose than customarily used for adults actively using opioids, and that non-opioid-tolerant pre-release prisoners can be successfully inducted onto therapeutic doses prior to release.
RCT Entities:
BACKGROUND: In a previously reported randomized controlled trial, formerly opioid-dependent prisoners were more likely to enter community drug abuse treatment when they were inducted in prison onto buprenorphine/naloxone (hereafter called buprenorphine) than when they received counseling without buprenorphine in prison (47.5% vs. 33.7%, p=0.012) (Gordon et al., 2014). In this communication we report on the results of the induction schedule and the adverse event profile seen in pre-release prisoners inducted onto buprenorphine. METHOD: This paper examines the dose induction procedure, a comparison of the proposed versus actual doses given per week, and side effects reported for 104 adult participants who were randomized to buprenorphine treatment in prison. Self-reported side effects were analyzed using generalized estimated equations to determine changes over time in side effects. RESULTS: Study participants were inducted onto buprenorphine at a rate faster than the induction schedule. Of the 104 (72 males, 32 females) buprenorphine recipients, 64 (37 males, 27 females) remained on medication at release from prison. Nine participants (8.6%) discontinued buprenorphine because of unpleasant opioid side effects. There were no serious adverse events reported during the in-prison phase of the study. Constipation was the most frequent symptom reported (69 percent). CONCLUSION: Our findings suggest that buprenorphine administered to non-opioid-tolerant adults should be started at a lower, individualized dose than customarily used for adults actively using opioids, and that non-opioid-tolerant pre-release prisoners can be successfully inducted onto therapeutic doses prior to release.
Authors: Nickolas Zaller; Michelle McKenzie; Peter D Friedmann; Traci C Green; Samuel McGowan; Josiah D Rich Journal: J Subst Abuse Treat Date: 2013-03-27
Authors: Josiah D Rich; Michelle McKenzie; Samuel Dickman; Jeffrey Bratberg; Joshua D Lee; Robert P Schwartz Journal: Addict Disord Their Treat Date: 2011-12
Authors: Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci Journal: Drug Alcohol Depend Date: 2017-01-11 Impact factor: 4.492
Authors: Michael S Gordon; Thomas R Blue; Kathryn Couvillion; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci Journal: Drug Alcohol Depend Date: 2018-05-12 Impact factor: 4.492
Authors: Elizabeth Needham Waddell; Sandra A Springer; Lisa A Marsch; David Farabee; Robert P Schwartz; Amesika Nyaku; Rusty Reeves; Keith Goldfeld; Ryan D McDonald; Mia Malone; Anna Cheng; Elizabeth C Saunders; Laura Monico; Jan Gryczynski; Kathleen Bell; Kasey Harding; Sandra Violette; Thomas Groblewski; Wendy Martin; Kasey Talon; Nicole Beckwith; Andrew Suchocki; Randy Torralva; Jennifer P Wisdom; Joshua D Lee Journal: J Subst Abuse Treat Date: 2021-04-08
Authors: Lori Regenstreif; Marina Sadik; Erin Beaulieu; Claire Bodkin; Lori Kiefer; Dale Guenter; Patsy W P Lee; Fiona G Kouyoumdjian Journal: Health Justice Date: 2022-03-02
Authors: Olivia K Sugarman; Marcus A Bachhuber; Ashley Wennerstrom; Todd Bruno; Benjamin F Springgate Journal: PLoS One Date: 2020-01-21 Impact factor: 3.240